PHVS

Pharvaris N.V. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website arvaris.com
Employees(FY) 70
ISIN NL00150005Y4

Performance

+3.33%

-3.3%

+9.63%

+0.74%

-26.92%

YTD

+34.87%

Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Advanced Technical Analysis

Technical Analysis of PHVS 2024-11-20

The stock indicators reflect a bearish sentiment, with the Moving Average Score at 10, Oscillators Score at 36, and a Technical Score of 23, indicating overall weakness in price momentum and suggesting caution for potential investors. The low scores across all categories highlight a lack of bullish signals in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of PHVS

Stock Rank

Recent News & Updates

2024-11-13 16:10
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates(GlobeNewswire)
2024-11-13 03:10
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates(Globenewswire)
2024-11-12 06:50
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference(GlobeNewswire)
2024-11-11 17:50
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference(Globenewswire)
2024-10-29 18:00
Axonis Therapeutics Announces $115 Million Series A Financing(Prnewswire)
2024-10-24 08:00
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting(GlobeNewswire)
2024-10-23 20:00
Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting(Globenewswire)
2024-10-16 06:50
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings(GlobeNewswire)
2024-10-15 18:50
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings(Globenewswire)
2024-10-15 06:50
Pharvaris to Host Virtual Investor Event on October 23, 2024(GlobeNewswire)
2024-10-14 18:50
Pharvaris to Host Virtual Investor Event on October 23, 2024(Globenewswire)
2024-10-03 06:50
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop(GlobeNewswire)
2024-10-02 18:50
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop(Globenewswire)
2024-09-19 09:50
JonesTrading Initiates Coverage on Pharvaris With Buy Rating, $46 Price Target(MT Newswires)
2024-09-19 08:36
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans(Simply Wall St.)
2024-09-05 06:50
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant(GlobeNewswire)
2024-09-05 06:49
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024(GlobeNewswire)
2024-09-05 06:48
Pharvaris Presents Data at the Bradykinin Symposium 2024(GlobeNewswire)
2024-09-04 18:50
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant(Globenewswire)
2024-09-04 18:49
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024(Globenewswire)
2024-09-04 18:48
Pharvaris Presents Data at the Bradykinin Symposium 2024(Globenewswire)
2024-08-28 06:50
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium(GlobeNewswire)
2024-08-27 18:50
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium(Globenewswire)
2024-08-14 06:50
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update(GlobeNewswire)
2024-08-13 18:50
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-07-16 16:02
Three Surprising Names That Could Be On Biogen's Buyout Shortlist(Investor's Business Daily)
2024-07-16 11:55
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense(Investor's Business Daily)
2024-06-11 06:50
Pharvaris Announces Annual Meeting of Shareholders(GlobeNewswire)
2024-06-10 18:50
Pharvaris Announces Annual Meeting of Shareholders(Globenewswire)
2024-06-04 06:50
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses(GlobeNewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.